Organization | Fortune Rock

Fortune Rock Report issue

For profit Phase 1 Phase 2

Founded: Beijing China (1993)

Status: No NME R&D (1993)

Organization Overview

First Clinical Trial

2012

NCT01919710

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2018

Timeline

NOW

Now

Alternative names

Beijing Bio-Fortune Ltd. | Tianjin SinoBiotech Ltd.

Active Ingredients

Drugs in Phase 2 Trials (6)

albumin (Human) (Plasbumin) (3 trials)

filgrastim (neupogen) (1 trial)

hsa-gcsf (3 trials)

interferon alpha-2a (roferon-a) (2 trials)

interferon alpha-2b (Intron-A) (4 trials)

sargramostim (leukine) (2 trials)

Drugs in Phase 1 Trials (3)

erythropoetin beta (1 trial)

human serum albumin/interferon alpha2b fusion protein (1 trial)

rHSA/EPO (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 1)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis B (Phase 2)

Hepatitis B, Chronic (Phase 2)

Hepatitis, Chronic (Phase 2)

Neutropenia (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 9
# of Trial APIs: 9